Among the various cochlear implant systems approved by the Food and Drug Administration, current labeling for pediatric usage encompasses (1) bilateral profound bilateral sensorineural hearing loss in children aged 9 to 24 months and bilateral severe to profound sensorineural hearing loss in children older than 2 years; (2) use of appropriately fitted hearing aids for 3 months (this can be waived if there is evidence of ossification); and (3) demonstration of limited progress with auditory, speech, and language development. Pediatric guidelines require children to have significantly worse speech understanding before qualifying for cochlear implantation. The early years of life have been shown to be critical for speech and language development, and auditory deprivation is especially detrimental during this crucial time. Level of evidence: 2.
|Original language||English (US)|
|Journal||Otolaryngology - Head and Neck Surgery (United States)|
|State||Accepted/In press - 2021|
- cochlear implantation
- health-related quality of life
- neurologically impaired
ASJC Scopus subject areas